Vaccination of Alzheimer's model mice with adenovirus vector containing quadrivalent foldable Aβ1-15 reduces Aβ burden and behavioral impairment without Aβ-specific T cell response

Journal of the Neurological Sciences

Volumn 272, Issue 1-2, 2008, Pages 87-98

  Zou, Juntao ^a   Yao, Zhibin ^a   Zhang, Ge ^b   Wang, Huaqiao ^a   Xu, Jie ^a   Yew, David T ^c   Forster, E Lucy ^c  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Alzheimer's disease; Immunotherapy; Multivalent adenovirus vaccine; T cell immune response; Transgenic mice

Indexed keywords

ADENOVIRUS VECTOR; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-15]; EPITOPE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G1; INTERLEUKIN 4;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BEHAVIOR DISORDER; BRAIN; CELL PROLIFERATION; CELL STIMULATION; CELLULAR IMMUNITY; COGNITIVE DEFECT; CONTROLLED STUDY; EMBRYO; GENE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; SPLEEN CELL; T LYMPHOCYTE; TH2 CELL; VACCINATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC VECTORS; HUMANS; MAZE LEARNING; MENTAL DISORDERS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; REACTION TIME; T-LYMPHOCYTES; VACCINATION;

EID: 48349117119     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2008.05.003     Document Type: Article

References (39)

1. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
2. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2000) 982-985
3. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 (2000) 979-982
4. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., and Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9 (2003) 448-452
5. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Muller-Tillmanns B., et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38 (2003) 547-554
6. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61 (2003) 46-54
7. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 (2005) 1553-1562
8. Geylis V., Kourilov V., Meiner Z., Nennesmo I., Bogdanovic N., and Steinitz M. Human monoclonal antibodies against amyloid-beta from healthy adults. Neurobiol Aging 26 (2005) 597-606
9. Lemere C.A., Beierschmitt A., Iglesias M., Spooner E.T., Bloom J.K., Leverone J.F., et al. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol 165 (2004) 283-297
10. McLaurin J., Cecal R., Kierstead M.E., Tian X., Phinney A.L., Manea M., et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8 (2002) 1263-1269
11. Cribbs D.H., Ghochikyan A., Vasilevko V., Tran M., Petrushina I., Sadzikava N., et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 15 (2003) 505-514
12. Monsonego A., Maron R., Zota V., Selkoe D.J., and Weiner H.L. Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl Acad Sci U S A 98 (2001) 10273-10278
13. Agadjanyan M.G., Ghochikyan A., Petrushina I., Vasilevko V., Movsesyan N., Mkrtichyan M., et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 174 (2005) 1580-1586
14. Seabrook T.J., Thomas K., Jiang L., Bloom J., Spooner E., Maier M., et al. Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice. Neurobiol Aging 28 (2007) 813-823
15. Sigurdsson E.M., Knudsen E., Asuni A., Fitzer-Attas C., Sage D., Quartermain D., et al. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J Neurosci 24 (2004) 6277-6282
16. Moretto N., Bolchi A., Rivetti C., Imbimbo B.P., Villetti G., Pietrini V., et al. Conformation-sensitive antibodies against Alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide. J Biol Chem 282 (2007) 11436-11445
17. Maier M., Seabrook T.J., Lazo N.D., Jiang L., Das P., Janus C., et al. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J Neurosci 26 (2006) 4717-4728
18. Kim H.D., Tahara K., Maxwell J.A., Lalonde R., Fukuiwa T., Fujihashi K., et al. Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease. J Gene Med 9 (2007) 88-98
19. Kim H.D., Maxwell J.A., Kong F.K., Tang D.C., and Fukuchi K. Induction of anti-inflammatory immune response by an adenovirus vector encoding 11 tandem repeats of Abeta1-6: toward safer and effective vaccines against Alzheimer's disease. Biochem Biophys Res Commun 336 (2005) 84-92
20. Kim H.D., Cao Y., Kong F.K., Van Kampen K.R., Lewis T.L., Ma Z., et al. Induction of a Th2 immune response by co-administration of recombinant adenovirus vectors encoding amyloid beta-protein and GM-CSF. Vaccine 23 (2005) 2977-2986
21. Zhang J., Wu X., Qin C., Qi J., Ma S., Zhang H., et al. A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease. Neurobiol Dis 14 (2003) 365-379
22. Hara H., Monsonego A., Yuasa K., Adachi K., Xiao X., Takeda S., et al. Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease. J Alzheimer's Dis 6 (2004) 483-488
23. Mouri A., Noda Y., Hara H., Mizoguchi H., Tabira T., and Nabeshima T. Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. Faseb J 21 (2007) 2135-2148
24. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 16 (2005) 1016-1027
25. Disis M.L., Shiota F.M., McNeel D.G., and Knutson K.L. Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens. Immunobiology 207 (2003) 179-186
26. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274 (1996) 99-102
27. Qu B.X., Xiang Q., Li L., Johnston S.A., Hynan L.S., and Rosenberg R.N. Abeta(42) gene vaccine prevents Abeta(42) deposition in brain of double transgenic mice. J Neurol Sci 260 (2007) 204-213
28. Ahlers J.D., Dunlop N., Alling D.W., Nara P.L., and Berzofsky J.A. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. J Immunol 158 (1997) 3947-3958
29. Torres K.C., Dutra W.O., and Gollob K.J. Endogenous IL-4 and IFN-gamma are essential for expression of Th2, but not Th1 cytokine message during the early differentiation of human CD4+ T helper cells. Hum Immunol 65 (2004) 1328-1335
30. Bensadoun J.C., and Aebischer P. Viral vectors as a tool to model and treat Parkinson's disease. Wien Klin Wochenschr 118 (2006) 568-570
31. Kim H.D., Kong F.K., Cao Y., Lewis T.L., Kim H., Tang D.C., et al. Immunization of Alzheimer model mice with adenovirus vectors encoding amyloid beta-protein and GM-CSF reduces amyloid load in the brain. Neurosci Lett 370 (2004) 218-223
32. Li S.B., Wang H.Q., Lin X., Xu J., Xie Y., Yuan Q.F., et al. Specific humoral immune responses in rhesus monkeys vaccinated with the Alzheimer's disease-associated beta-amyloid 1-15 peptide vaccine. Chin Med J (Engl) 118 (2005) 660-664
33. Leverone J.F., Spooner E.T., Lehman H.K., Clements J.D., and Lemere C.A. Abeta1-15 is less immunogenic than Abeta1-40/42 for intranasal immunization of wild-type mice but may be effective for "boosting". Vaccine 21 (2003) 2197-2206
34. Hartman R.E., Izumi Y., Bales K.R., Paul S.M., Wozniak D.F., and Holtzman D.M. Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J Neurosci 25 (2005) 6213-6220
35. Lemere C.A., Spooner E.T., LaFrancois J., Malester B., Mori C., Leverone J.F., et al. Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol Dis 14 (2003) 10-18
36. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., and Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 98 (2001) 8850-8855
37. DaSilva K., Brown M.E., Westaway D., and McLaurin J. Immunization with amyloid-beta using GM-CSF and IL-4 reduces amyloid burden and alters plaque morphology. Neurobiol Dis 23 (2006) 433-444
38. Monsonego A., and Weiner H.L. Immunotherapeutic approaches to Alzheimer's disease. Science 302 (2003) 834-838
39. Lewis P.J., van Drunen Littel-van den H., and Babiuk L.A. Altering the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response. J Virol 73 (1999) 10214-10223